Attached files
| file | filename |
|---|---|
| S-1 - FORM S-1 - K-V Pharmaceutical Co | ds1.htm |
| EX-5.1 - OPINION OF THOMPSON COBURN LLP - K-V Pharmaceutical Co | dex51.htm |
| EX-23.3 - CONSENT OF KPMG, LLP - K-V Pharmaceutical Co | dex233.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
The Board of Directors
K-V Pharmaceutical Company
Bridgeton, Missouri
We hereby consent to the use in the prospectus constituting a part of this Registration Statement of our report dated December 23, 2010 relating to the consolidated financial statements and 2010 information in Schedule II of K-V Pharmaceutical Company, which is contained in that prospectus. Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the prospectus.
/s/ BDO USA, LLP
Chicago, Illinois
May 6, 2011